Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $130.00 Price Target at Morgan Stanley

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target increased by Morgan Stanley from $101.00 to $130.00 in a research report report published on Thursday, November 9th. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on ALNY. Cowen restated an outperform rating and issued a $151.00 target price (up from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Credit Suisse Group raised their price target on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an outperform rating in a research report on Friday, November 3rd. Needham & Company LLC reaffirmed a buy rating and issued a $152.00 price target (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. J P Morgan Chase & Co raised shares of Alnylam Pharmaceuticals from a neutral rating to an overweight rating in a research report on Thursday, November 9th. Finally, Barclays raised their price target on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an overweight rating in a research report on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $121.85.

Shares of Alnylam Pharmaceuticals (ALNY) opened at $129.74 on Thursday. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a 12 month low of $35.98 and a 12 month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to analyst estimates of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business’s quarterly revenue was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.21) earnings per share. research analysts predict that Alnylam Pharmaceuticals will post -5.21 EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 73,415 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total transaction of $9,610,023.50. Following the transaction, the chief executive officer now owns 223,125 shares of the company’s stock, valued at approximately $29,207,062.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. In the last three months, insiders have sold 363,212 shares of company stock worth $44,032,736. Insiders own 4.30% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. State of Wisconsin Investment Board raised its holdings in shares of Alnylam Pharmaceuticals by 0.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 100 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares during the period. Utah Retirement Systems raised its holdings in shares of Alnylam Pharmaceuticals by 1.5% in the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock worth $1,100,000 after purchasing an additional 200 shares during the period. Prudential Financial Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 4.8% in the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 200 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock worth $3,818,000 after purchasing an additional 398 shares during the period. 88.43% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/morgan-stanley-raises-alnylam-pharmaceuticals-inc-alny-price-target-to-130-00/1771775.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.